EP3464608A4 - Therapeutische rekombinante klotho-proteine sowie zusammensetzungen und verfahren damit - Google Patents

Therapeutische rekombinante klotho-proteine sowie zusammensetzungen und verfahren damit Download PDF

Info

Publication number
EP3464608A4
EP3464608A4 EP17807601.4A EP17807601A EP3464608A4 EP 3464608 A4 EP3464608 A4 EP 3464608A4 EP 17807601 A EP17807601 A EP 17807601A EP 3464608 A4 EP3464608 A4 EP 3464608A4
Authority
EP
European Patent Office
Prior art keywords
compositions
same
methods involving
therapeutic recombinant
klotho proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17807601.4A
Other languages
English (en)
French (fr)
Other versions
EP3464608A1 (de
Inventor
Joseph F. Tarsio
Dinesh RATURI
James R. PLANTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Klotho Therapeutics Inc
Original Assignee
Klotho Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klotho Therapeutics Inc filed Critical Klotho Therapeutics Inc
Publication of EP3464608A1 publication Critical patent/EP3464608A1/de
Publication of EP3464608A4 publication Critical patent/EP3464608A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
EP17807601.4A 2016-06-02 2017-06-02 Therapeutische rekombinante klotho-proteine sowie zusammensetzungen und verfahren damit Pending EP3464608A4 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662344743P 2016-06-02 2016-06-02
US201662375046P 2016-08-15 2016-08-15
US201662401600P 2016-09-29 2016-09-29
US201662425237P 2016-11-22 2016-11-22
US201762456318P 2017-02-08 2017-02-08
PCT/US2017/035755 WO2017210607A1 (en) 2016-06-02 2017-06-02 Therapeutic recombinant klotho proteins and compositions and methods involving the same

Publications (2)

Publication Number Publication Date
EP3464608A1 EP3464608A1 (de) 2019-04-10
EP3464608A4 true EP3464608A4 (de) 2020-01-29

Family

ID=60477890

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17807601.4A Pending EP3464608A4 (de) 2016-06-02 2017-06-02 Therapeutische rekombinante klotho-proteine sowie zusammensetzungen und verfahren damit

Country Status (9)

Country Link
EP (1) EP3464608A4 (de)
JP (2) JP2019526272A (de)
KR (2) KR102570250B1 (de)
CN (2) CN116478907A (de)
AU (1) AU2017272349B2 (de)
BR (1) BR112018073909A2 (de)
CA (1) CA3025461A1 (de)
MX (2) MX2018014753A (de)
WO (1) WO2017210607A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017363321B2 (en) * 2016-11-22 2023-09-28 Klotho Therapeutics, Inc. Novel recombinant Klotho proteins and compositions and methods involving the same
CN108333355B (zh) * 2018-02-01 2020-05-26 黄曙 Klotho蛋白在制备诊断胃肠道间质瘤危险度的试剂中的用途
CN108384747A (zh) * 2018-03-05 2018-08-10 安徽省农业科学院园艺研究所 表达狂犬抗体的cho细胞无血清悬浮培养方法
CN109251896A (zh) * 2018-08-13 2019-01-22 中山大学 一株高表达hKLs-his蛋白的细胞株及其制备方法和应用
WO2020160617A1 (en) * 2019-02-05 2020-08-13 Helium 3 Biotech Pty Ltd A membrane protein expression and distribution modulating composition and method of use thereof
RU2712770C1 (ru) * 2019-05-21 2020-01-31 Всеволод Викторович Мелехин Способ ингибирования роста опухолевых клеток
IT201900007446A1 (it) 2019-05-29 2020-11-29 Giuseppe Castellano Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
US11891615B2 (en) 2020-06-10 2024-02-06 Gail Marion Humble Process to produce Klotho protein in vitro
CN112195165A (zh) * 2020-10-15 2021-01-08 广东药科大学 一种抗衰老分泌型Klotho蛋白及其编码基因、重组表达载体与应用
CN114487218B (zh) * 2020-10-23 2023-11-14 北京红惠新医药科技有限公司 β-烟酰胺单核苷酸的分析方法
CN112915193B (zh) * 2021-03-05 2022-09-13 南方医科大学南方医院 Kp-1在制备治疗慢性肺病的药物中的用途
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法
CN113215199A (zh) * 2021-04-29 2021-08-06 广州博识生物科技有限公司 一种Klotho+/-基因缺失斑马鱼
WO2022243519A1 (en) * 2021-05-21 2022-11-24 Universitat Autònoma De Barcelona Secreted splicing variant of klotho for treating bone disorders
CN113409306A (zh) * 2021-07-15 2021-09-17 推想医疗科技股份有限公司 一种检测装置、训练方法、训练装置、设备和介质
WO2023172444A2 (en) * 2022-03-08 2023-09-14 Mayo Foundation For Medical Education And Research Senotherapeutic agents and alpha-klotho polypeptides
WO2023218445A1 (en) * 2022-05-08 2023-11-16 Ichilov Tech Ltd. Klotho derivatives with modified structure

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027885A1 (fr) * 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Nouveau popypeptide chimerique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303394B2 (en) * 2002-12-23 2009-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
CN102861343A (zh) * 2012-10-17 2013-01-09 南方医科大学 分泌型Klotho在制备治疗慢性肾脏病的药物中的应用
SG11201608557UA (en) * 2014-04-16 2016-11-29 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027885A1 (fr) * 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Nouveau popypeptide chimerique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KATO YUKINARI ET AL: "Establishment of the anti-Klotho monoclonal antibodies and detection of Klotho protein in kidneys", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 267, no. 2, 19 January 2000 (2000-01-19), pages 597 - 602, XP002572556, ISSN: 0006-291X, DOI: 10.1006/BBRC.1999.2009 *
YAMAZAKI Y ET AL: "Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 398, no. 3, 30 July 2010 (2010-07-30), pages 513 - 518, XP027185031, ISSN: 0006-291X, [retrieved on 20100701], DOI: 10.1016/J.BBRC.2010.06.110 *

Also Published As

Publication number Publication date
JP2019526272A (ja) 2019-09-19
CN109219663A (zh) 2019-01-15
KR20230125857A (ko) 2023-08-29
KR102570250B1 (ko) 2023-08-29
KR20190015711A (ko) 2019-02-14
WO2017210607A1 (en) 2017-12-07
MX2018014753A (es) 2019-06-17
BR112018073909A2 (pt) 2019-02-26
AU2017272349B2 (en) 2022-12-01
AU2017272349A1 (en) 2018-11-22
MX2023008626A (es) 2023-08-08
CA3025461A1 (en) 2017-12-07
EP3464608A1 (de) 2019-04-10
JP2023123565A (ja) 2023-09-05
CN116478907A (zh) 2023-07-25

Similar Documents

Publication Publication Date Title
EP3464608A4 (de) Therapeutische rekombinante klotho-proteine sowie zusammensetzungen und verfahren damit
EP3623388A4 (de) Bispezifisches rekombinantes protein und verwendung davon
EP3538561A4 (de) Rna-geführte polypeptidvarianten und verfahren zur verwendung
HK1257373A1 (zh) 雙功能蛋白質和包含其的藥物組合物
EP3380125A4 (de) Konjugate mit peptidgruppen und zugehörige verfahren
EP3454832A4 (de) Gdf15-fusionsproteine und verwendungen davon
EP3551212A4 (de) Neuartige rekombinante klotho-proteine sowie zusammensetzungen und verfahren damit
EP3235830A4 (de) Interleukin-15-proteinkomplex und verwendung davon
IL265489B (en) Recombinant binding proteins and their uses
EP3596104A4 (de) Zusammensetzungen mit pedf-abgeleiteten kurzen peptiden und verwendungen davon
EP3633034A4 (de) Modifiziertes cas9-protein und verwendung davon
EP3310376A4 (de) Modifizierte therapeutische mittel und zusammensetzungen daraus
EP3518971A4 (de) Antikörper und therapeutische proteinformulierungen sowie verwendungen davon
EP3536792A4 (de) Rekombinante hefe und verwendung davon
EP3444270A4 (de) Neuartiges natürliches protein und anwendung davon
EP3290441A4 (de) Rgma-bindendes protein und verwendung davon
EP3393586A4 (de) Kombinationstherapie aus bromodomänen- und extra-terminal-proteinhemmer
EP3678701A4 (de) Therapeutische proteinzusammensetzungen und verfahren zur herstellung und verwendung davon
EP3436467A4 (de) Neuartige zusammensetzungen und therapeutische verfahren
EP3722305A4 (de) Hm-3-fusionsprotein und verwendung davon
EP3708661A4 (de) Therapeutisches enzymfusionsprotein mit neuartiger struktur und dessen verwendung
EP3642219A4 (de) Peptidzusammensetzungen und zugehörige verfahren
ZA202101250B (en) Novel crispr-associated protein and use thereof
EP3523321A4 (de) Zusammensetzungen und verfahren zur proteinexpression und -abgabe
EP4013445A4 (de) Therapeutische proteinzusammensetzungen und verfahren

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200108

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/18 20060101ALI20191220BHEP

Ipc: A61K 38/22 20060101ALI20191220BHEP

Ipc: C12P 21/06 20060101AFI20191220BHEP

Ipc: A61K 38/17 20060101ALI20191220BHEP